On March 20, 2012, the U.S. Supreme Court handed down its decision in Mayo Collaborative Services, et al v. Prometheus Laboratories, Inc (â€œMayoâ€) and ended an eight-year legal battle over patents covering processes for determining patient-specific dosing for a thiopurine drug to treat autoimmune diseases.Â In a unanimous decision, the Court held that the claimed processes are not patent-eligible subject matter under 35 U.S.C. Â§101 of the U.S. patent laws, and overturned the decision of the Court of Appeals for the Federal Circuit.
The Supreme Court decision in Mayo established that the machine-or-transformation test is not the definitive test for determining the patent-eligibility of process claims, including process claims that embody laws of nature or natural phenomena.Â In its analysis, the Court determined considered whether the claims were drawn to patent eligible subject matter as provided under 35 U.S.C. Â§101 of the U.S. patent laws, or patent ineligible subject matter excepted from Â§101.Â The Court held that the process claims were essentially drawn to the laws of nature themselves and thus fell into the laws-of-nature exception to Â§101.Â The process claims did not cover patent-eligible processes of applying certain laws of nature.Â This decision has clear implications for the biotechnology industry that go beyond diagnostics and personalized medicine. As such, biotechnology companies should consider re-evaluating their patent position and adapting their patent strategies in view of Mayo.
Case No. 10-1150, decided March 20, 2012
447 U.S. 303 (1980)
409 U.S. 63 (1972)
333 U.S. 127 (1948)
Gottshalk v. Benson, 409 U.S. 63 (1972)
Case No. 04-CV-1200, 2008 WL 878910 (S.D. Cal. 2008)
581 F. 3d 1336 (Fed. Cir. 2009)
See also In re Bilski, 545 F. 3d 843 ( Fed Cir. 2008)
545 F. 3d 843 ( Fed Cir. 2008)
130 S. Ct. 3218 (2010)
Case No. 2008-1403, decided Dec. 17, 2010
Case No. 10-1150, decided Mar. 20, 2012
Case No. 2010-1406, decided July 29, 2011
Unless specified by prior arrangement, the author agrees to the following terms and assurances:
- For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
- I/we further give to the following assurances
- I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
- I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
- To the best of my/our knowledge, all the facts in the contribution are true and accurate;
- The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
- Nothing in the contribution is obscene or libellous;
- Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
- I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).